GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...
Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...
GSK and Empirico ink license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases: London, UK Wednesday, October 29, 2025, 09:00 Hr ...
Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving ...
Providence Holy Cross Medical Center is the first Providence hospital in the San Fernando Valley to offer a minimally ...
Anti-IL5 therapy significantly reduces moderate and severe exacerbations in asthma and COPD, preventing major ...
GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...
UK pharma major GSK and US clinical-stage biotech Empirico, with leading capabilities in human genetics-driven target ...
Vibhor Gupta, PhD, founder & CEO of patient data AI platform Pangaea Data, highlights a widespread failure to extract value ...
Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan ...
Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic ...
Roxane Wellman remembers standing at the back of the auditorium at the start of last year's UC Davis Asthma Network (UCAN) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback